# Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections

> **NCT06549530** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Bavarian Nordic** · enrollment: 460 (estimated)

## Conditions studied

- Monkeypox (Mpox)

## Interventions

- **DRUG:** MVA-BN

## Key facts

- **NCT ID:** NCT06549530
- **Lead sponsor:** Bavarian Nordic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-21
- **Primary completion:** 2026-05-01
- **Final completion:** 2026-05-07
- **Target enrollment:** 460 (ESTIMATED)
- **Last updated:** 2025-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06549530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06549530, "Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06549530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*